IP Library Granted Patent US 11,260,133
Granted Patent B2
US 11,260,133 · App. 12/390,061 · Granted Mar 1, 2022

Methods and compositions related to peptides and proteins with C-terminal elements

Inventors: Erkki Ruoslahti (Buellton, CA); Tambet Teesalu (Goleta, CA); Kazuki Sugahara (Goleta, CA)
Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
A61K47/6923A61K47/62A61K47/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,260,133
App. No.
12/390,061
Granted
Mar 1, 2022
Kind
B2
Abstract

Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.

Claims (14)

1. A method of forming a CendR conjugate, the method comprising

(a) selecting an amino acid sequence comprising a CendR element for internalization into a cell, tissue penetration, or both, wherein the CendR element is at a C-terminal end of the conjugate and has an exposed C-terminal carboxyl group, wherein the CendR element has the sequence X 1 X 2 X 3 X 4 , where X 1 can be R, or K, where X 4 can be R, K, or KG, and where X 2 and X 3 can each be, independently, any amino acid, wherein X 1 and X 4 are not both R, and wherein the CendR element does not include KLRK (SEQ ID NO:168), KPPR (SEQ ID NO:169), KRSR (SEQ ID NO:170), KWKK (SEQ ID NO:173), RRLK (SEQ ID NO:178), RRTK (SEQ ID NO:183), RRPK (SEQ ID NO:184), KQRR (SEQ ID NO:185), KRAR (SEQ ID NO:186), KRGR (SEQ ID NO:187), RSFK (SEQ ID NO:188), KKPR (SEQ ID NO:189), RLAK (SEQ ID NO:174), or KRTR (SEQ ID NO:191), and

(b) causing a cargo composition to be covalently coupled or non-covalently associated with a protein or peptide comprising the selected amino acid sequence,

wherein the cargo composition is coupled or associated with the protein or peptide on the N terminal side of the CendR element,

wherein the CendR conjugate comprises the protein or peptide and the coupled or associated cargo composition,

wherein the CendR element binds to neuropilin 1 (NRP-1), wherein internalization of the CendR element into cells is dependent on NRP-1, and

wherein the CendR element has the sequence KLAK (amino acids 11-14 of SEQ ID NO:5), KPAR (amino acids 4-7 of SEQ ID NO:114), KPER (amino acids 4-7 of SEQ ID NO:90), KPLR (amino acids 4-7 of SEQ ID NO:63), KPRR (amino acids 5-8 of SEQ ID NO:126), KQAR (amino acids 4-7 of SEQ ID NO:64), KRDR (amino acids 3-6 of SEQ ID NO:89), KRER (amino acids 4-7 of SEQ ID NO:91), KTAR (amino acids 3-6 of SEQ ID NO:56), RGDK (amino acids 2-5 of SEQ ID NO:4), RPAK (amino acids 4-7 of SEQ ID NO:112), or RTPK (amino acids 4-7 of SEQ ID NO:84).

2. A CendR conjugate made by the method comprising

(a) selecting an amino acid sequence for internalization into a cell, tissue penetration, or both, wherein the amino acid sequence comprises a CendR element, wherein the CendR element is at a C-terminal end of the conjugate and has an exposed C-terminal carboxyl group, wherein the CendR element has the sequence X 1 X 2 X 3 X 4 , where X 1 can be R, or K, where X 4 can be R, K, or KG, and where X 2 and X 3 can each be, independently, any amino acid, wherein X 1 and X 4 are not both R, and wherein the CendR element does not include KLRK (SEQ ID NO:168), KPPR (SEQ ID NO:169), KRSR (SEQ ID NO:170), KWKK (SEQ ID NO:173), RRLK (SEQ ID NO:178), RRTK (SEQ ID NO:183), RRPK (SEQ ID NO:184), KQRR (SEQ ID NO:185), KRAR (SEQ ID NO:186), KRGR (SEQ ID NO:187), RSFK (SEQ ID NO:188), KKPR (SEQ ID NO:189), RLAK (SEQ ID NO:174), or KRTR (SEQ ID NO:191), and

(b) causing a cargo composition to be covalently coupled or non-covalently associated with a protein or peptide comprising the selected amino acid sequence,

wherein the cargo composition is coupled or associated with the protein or peptide on the N terminal side of the CendR element,

wherein the CendR conjugate comprises the protein or peptide and the coupled or associated cargo composition,

wherein the CendR element binds to neuropilin 1 (NRP-1), wherein internalization of the CendR element into cells is dependent on NRP-1, and

wherein the CendR element has the sequence KLAK (amino acids 11-14 of SEQ ID NO:5), KPAR (amino acids 4-7 of SEQ ID NO:114), KPER (amino acids 4-7 of SEQ ID NO:90), KPLR (amino acids 4-7 of SEQ ID NO:63), KPRR (amino acids 5-8 of SEQ ID NO:126), KQAR (amino acids 4-7 of SEQ ID NO:64), KRDR (amino acids 3-6 of SEQ ID NO:89), KRER (amino acids 4-7 of SEQ ID NO:91), KTAR (amino acids 3-6 of SEQ ID NO:56), RGDK (amino acids 2-5 of SEQ ID NO:4), RPAK (amino acids 4-7 of SEQ ID NO:112), or RTPK (amino acids 4-7 of SEQ ID NO:84).

Assignments (2)
CHANGE OF NAME Recorded Dec 3, 2010
From: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
To: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Reel/Frame 025442/0892 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2009
From: RUOSLAHTI, ERKKI; TEESALU, TAMBET; SUGAHARA, KAZUKI
To: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 022830/0128 →
Continuity (2)
Provisional Application 61030409 · Feb 21, 2008
Related Publication 20090226372A1 · Sep 10, 2009
Cited By (1)
US 12,351,653